Regulatory News:
This press release is not intended for
publication or distribution in the United States, Canada, Japan or
Australia
MaaT Pharma (EURONEXT: MAAT – the “Company”), a French
clinical-stage biotech and a pioneer in the development of
Microbiome Ecosystem Therapies™ (MET) dedicated to improving
survival outcomes for patients with cancer, today announced the
successful completion of a capital increase of approximately €12.7
million supported by its existing shareholders including Seventure
Partners, PSIM Fund represented by Bpifrance Investissement,
Biocodex, Invus, Céleste Management, Skyviews Life Sciences and
Tocqueville. The funds will support the Company’s biomanufacturing
expansion and ongoing and future clinical trials.
“We are very pleased with the success of this capital increase,
and the endorsement from our current investors. This transaction
puts MaaT Pharma in a very good position to ensure the
implementation of its ongoing and future clinical programs and to
support our efforts in obtaining non-dilutive funding. This is also
a major step that enables us to strengthen, even further, our
biomanufacturing processes in line with the encouraging recent
communication from the FDA moving us closer to our objective of
initiating the clinical evaluation of our pipeline in the U.S. in
parallel with the ongoing clinical program in Europe,” comments
Hervé Affagard, MaaT Pharma CEO and co-founder.
Impact on cash flow and use of proceeds
Gross proceeds from the transaction are €12,680,000. The
Company’s financial visibility will be extended from Q4 2023 into
Q2 2024. The Company plans to use the proceeds, along with existing
cash and cash equivalents, to finance biomanufacturing and
regulatory capabilities which will support the Company’s objective
to start clinical evaluation in the U.S. subject to the lifting of
the clinical hold, and for ongoing clinical development programs
for MaaT013 and MaaT033 as well as general corporate purposes.
Key characteristics of the share capital increase
MaaT Pharma’s Board of Directors using the delegation of powers
granted by the 18th resolution of the shareholders' general meeting
held on May 31st, 2022 (capital increase with cancellation of
preferential subscription rights in favor of categories of persons
with specific characteristics) and in accordance with article L.
225-138 et seq. of the French Commercial Code (code de commerce),
has decided on February 16, 2023 to complete a capital increase of
12,680,000 euros, by way of issuance of 1,585,000 new shares with a
nominal value of €0.10 each (the "New Shares") for a
subscription price of €8 each (including premium) (the "Capital
Increase").
The New Shares were issued at a price of €8, representing a
discount of 11% compared to the volume-weighted average of the
share price over the last three trading sessions preceding the
setting of the price per Share (i.e. the sessions of February 16,
15 and 14, 2023, the said average amounting to 8.99 euros).
Seventure Partners and Biocodex who are existing shareholders
and are also represented on the Board of Directors of the Company,
as well PSIM Fund represented by Bpifrance Investissement, also an
existing shareholder and observer at the Board of Directors of the
Company, will participate in the Capital Increase for subscription
amounts of 2 million euros, 2 million euros and 5 million euros
respectively, representing 70.98% of the aggregate gross amount of
the Capital Increase. It is specified that the subscribers who are
also members of MaaT Pharma’s Board of Directors did not take part
in the vote of the Capital Increase at the Board of Directors’
meeting held on February 16, 2023.
The subscriptions of existing shareholders to the Capital
Increase (including the participation of Seventure Partners,
Biocodex and PSIM Fund) represents 12.680 million euros, i.e. the
aggregate gross amount of the Capital Increase.
Following the settlement-delivery expected to occur on February
21, 2023, MaaT Pharma's share capital will amount to €1,153,173.90
divided into 11,531,739 shares. The New Shares will be fungible
with the existing shares of the Company and will be admitted to
trading on the regulated market of Euronext in Paris under the ISIN
FR0012634822.
Impact of the offering on the share capital
The issuance of the New Shares represents 13.74% of the share
capital of the Company after the Capital Increase. On an
illustrative basis, a shareholder holding 1% of the Company’s share
capital before the transaction will now hold a stake of 0.86% after
the transaction.
The following table specifies the evolution of the share capital
of the Company after the Capital Increase:
Shareholders
Before share capital
increase
After share capital
increase
Total number of shares (non
diluted basis)
% of capital and voting rights
(non diluted basis)
Total number of shares
(diluted basis)
% of capital and voting rights
(diluted basis)
Total number of shares (non
diluted basis)
% of capital and voting rights
(non diluted basis)
Total number of shares
(diluted basis)
% of capital and voting rights
(diluted basis)
Hervé Affagard
190 722
1,92%
313 473
2,97%
196 972
1,71%
319 723
2,64%
Total corporate officers
(individuals)
190 722
1,92%
313 473
2,97%
196 972
1,71%
319 723
2,64%
Seventure funds
2 345 236
23,58%
2 345 236
22,24%
2 595 236
22,51%
2 595 236
21,39%
Crédit Mutuel Innovation SAS
1 412 364
14,20%
1 412 364
13,39%
1 412 364
12,25%
1 412 364
11,64%
Biocodex SAS
977 905
9,83%
977 905
9,27%
1 227 905
10,65%
1 227 905
10,12%
Symbiosis LLC
2 027 702
20,39%
2 027 702
19,23%
2 027 702
17,58%
2 027 702
16,71%
FPCI Fonds PSIM
1 177 439
11,84%
1 177 439
11,16%
1 802 439
15,63%
1 802 439
14,86%
Other investors
342 743
3,45%
342 743
3,25%
796 493
6,91%
796 493
6,57%
Total historical shareholders
8 283 389
83,28%
8 283 389
78,54%
9 862 139
85,52%
9 862 139
81,30%
Employees and consultants
303 203
3,05%
779 983
7,40%
303 203
2,63%
779 983
6,43%
Self-holding
11 650
0,12%
11 650
0,11%
11 650
0,10%
11 650
0,10%
Free Float
1 157 775
11,64%
1 157 775
10,98%
1 157 775
10,04%
1 157 775
9,54%
Total
9 946 739
100,00%
10 546 270
100,00%
11 531 739
100,00%
12 131 270
100,00%
Information available to the public and risk factors
Investors' attention is drawn to the risk factors set out in the
2021 Universal Registration Document filed with the Autorité des
Marchés Financiers (AMF) on July 5, 2022 under number R.22-032 as
well as in the 2022 half-year financial report. This document, as
well as other regulated information and all of the Company's press
releases, can be consulted on the MaaT Pharma website:
www.maatpharma.com.
About MaaT Pharma
MaaT Pharma, a clinical stage biotechnology company, has
established a complete approach to restoring patient-microbiome
symbiosis in oncology. Committed to treating cancer and
graft-versus-host disease (GvHD), a serious complication of
allogeneic stem cell transplantation, MaaT Pharma has launched, in
March 2022 in Europe, a Phase 3 clinical trial for patients with
acute GvHD, following the achievement of its proof of concept in a
Phase 2 trial. Its powerful discovery and analysis platform,
gutPrint®, supports the development and expansion of its pipeline
by determining novel disease targets, evaluating drug candidates,
and identifying biomarkers for microbiome-related conditions. The
company’s Microbiome Ecosystem Therapies are produced through a
standardized cGMP manufacturing and quality control process to
safely deliver the full diversity of the microbiome, in liquid and
oral formulations. MaaT Pharma benefits from the commitment of
world-leading scientists and established relationships with
regulators to support the integration of the use of microbiome
therapies in clinical practice.
MaaT Pharma is the first company developing microbiome-based
therapies listed on Euronext Paris (ticker: MAAT).
Forward-looking statements
This press release contains forward-looking statements. All
statements other than statements of historical fact included in
this press release regarding future events are subject to (i)
change without notice and (ii) factors beyond the Company's
control. These statements may include, but are not limited to,
statements preceded by, followed by or including words such as
"target", "believe", "expect", "aim", "intend", "may", "forecast",
"estimate", "plan", "project", "will", "may have", "likely",
"should", "expect" and other words and terms of similar meaning or
the negative thereof. Forward-looking statements are subject to
inherent risks and uncertainties beyond the Company's control that
could cause the Company's actual results or performance to differ
materially from those expressed or implied by such forward-looking
statements.
Disclaimer
This announcement is an advertisement and not a prospectus
within the meaning of Directive 2003/71/EC of the European
Parliament and of the Council of 4 November 2003, as amended (the
“Prospectus Directive”).
In France, the Offering described above took place solely as a
placement to a category of institutional investors, in accordance
with Article L. 225-138 of the “Code de commerce” and applicable
regulations. The Offering does not constitute a public offering in
France, as defined in Article L. 411-1 of the “Code monétaire et
financier” and no prospectus reviewed or approved by the Autorité
des marchés financiers will be published.
With respect to Member States of the European Economic Area
(including France), no action has been taken or will be taken to
permit a public offering of the securities referred to in this
press release which would require the publication of a prospectus
in any Member State.
This press release and the information it contains is not an
offer to sell, nor the solicitation of an offer to subscribe for or
buy, New Shares in the United States or any other jurisdiction
where restrictions may apply. Securities may not be offered or sold
in the United States absent registration under the Securities Act
or an exemption from registration thereunder. MaaT Pharma does not
intend to register the New Shares under the Securities Act or
conduct a public offering of the New Shares in France, the United
States, or in any other jurisdiction.
This communication is being distributed only to, and is directed
only at (a) persons outside the United Kingdom, (b) persons who
have professional experience in matters relating to investments
falling within Article 19(5) of the Financial Services and Markets
Act 2000 (Financial Promotion) Order 2005 (the "Order"), and
(c) high net worth entities, and other persons to whom it may
otherwise lawfully be communicated, falling within Article 49(2) of
the Order (all such persons together being referred to as
"relevant persons"). Any investment or investment activity
to which this communication relates is available only to relevant
persons and will be engaged in only with relevant persons. Any
person who is not a relevant person should not act or rely on this
communication or any of its contents.
This distribution of this press release may be subject to legal
or regulatory restrictions in certain jurisdictions. Any person who
comes into possession of this press release must inform him or
herself of and comply with any such restrictions.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230216005878/en/
MaaT Pharma – Investor Relations Hervé AFFAGARD
Co-founder and CEO Siân CROUZET COO / CFO +33 4 28 29 14 00
invest@maat-pharma.com
MaaT Pharma – Media Relations Pauline RICHAUD Senior PR
& Corporate Communications Manager +33 6 14 06 45 92
prichaud@maat-pharma.com
Trophic Communications Corporate and Medical
Communications Jacob VERGHESE or Gretchen SCHWEITZER +49 171
351 27 33 maat@trophic.eu
Maat Pharma (EU:MAAT)
過去 株価チャート
から 11 2023 まで 12 2023
Maat Pharma (EU:MAAT)
過去 株価チャート
から 12 2022 まで 12 2023